Medicare proposes no changes for anemia drugs
Reuters, March 18, 2011
Medicare officials do not plan at this time to change payment terms for anemia drugs used in kidney patients who are undergoing dialysis.
The agency, which is slated to issue a final decision on the matter in June, also said it has found no clear proof that the drugs provide clinical benefits other than increasing hemoglobin.
Endorsement of current reimbursement guidelines would benefit shares of Amgen Inc, which rakes in billions from sales of its flagship Epogen anemia drug for treatment of kidney dialysis patients.
Most Viewed
Most Emailed
- Urologists 'Outraged' Over PSA Test Challenge
- New Facebook Page Gathers Stories of Medical Harm
- Luxury Hospital Facilities Put Patient Experience First
- Five Hospitals Share Three Secrets to Improve Knee Surgery Outcomes
- Heartland Health Joins Mayo Clinic Network
- Beleaguered Fairview Health CEO to Retire in July
- Health Insurance Exchanges Put Defined Benefits to the Test
- Challenging Physicians to Help Improve the ED
- For hospitals and insurers, new fervor to cut costs
- The Power of Plugged-In Physicians


Comments are moderated. Please be patient.